Denali Therapeutics Inc. (NASDAQ: DNLI) is a Healthcare company (Biotechnology) with a market capitalization of $2.9B. The Maz Rating grades it against the other companies in its sector.
Denali Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.00, Denali Therapeutics Inc. trades at 133.5x sales and 3.6x book value. Over the last twelve months it generated about $22M of revenue and a net loss of $280M. It runs a gross margin of 72.0%, an operating margin of -2488.1% and a net margin of -1470.5%. It shows return on equity of -34.0%, return on invested capital of -45.4% and a free cash flow yield of -15.7%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 6.21. Over the past 52 weeks the share price ranged from $15.34 to $27.30, with a beta of 1.08.
Denali Therapeutics Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 19 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Denali Therapeutics Inc. (DNLI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 5.41% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.4% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 5.41% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.3% / 33% · Receivables / Mkt Cap (36m) 0.49% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 5.41% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.3% / 33.33% · Receivables / Mkt Cap (24m) 0.49% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.55% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 63.9% / 33.33% · Receivables / Avg Assets (4Q) 0.55% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 16.7% / 33.33% · (Cash+ST Inv) / Total Assets 41.1% / 33.33% · (Cash+Recv) / Total Assets 42.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Denali Therapeutics Inc. (DNLI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Denali Therapeutics Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Denali Therapeutics Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.